Pin and immunotherapy combo for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment combining a drug called PIN with an immunotherapy (anti-PD1) for people with advanced liver cancer (HCC) that has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced liver cancer (HCC) that has not responded to or is no longer controllable with standard treatments like targeted therapy or immunotherapy.
- You have at least one tumor that can be measured and at least one tumor that can be injected (for example, in the skin, lymph node, or an organ) that is at least 10 mm wide.
- You are willing to have a new biopsy of your tumor during the study.
- Your liver function is fairly good (Child-Pugh class A or early B, and no major liver failure).
- You have not had major treatment (like chemotherapy, radiation, or major surgery) in the last 4 weeks, and you have recovered from any side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of two medicines, pin and sintilimab, for people with advanced colorectal cancer that has spread to the liver and has already been treated with at least two standard therapies. The study aims to see if injecting the medicine directly into the liver tumor, combined with immunotherapy through a vein, can shrink tumors and help patients live longer.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.